I think it is important to see the difference now
Post# of 148187
Kelly has been clear that the path forward for next steps in the cancer and Nash p2 trials is to be partnered for the next step. We have partnered with distributers but they are not involved with trials. all VC partnerships have been in very limited terms in cash for shares deals - not a future growth type partnership. The BP partnership is next and it is not a buyout deal, it is more of a show them what we have and let them decide if it is there best interest. Scott Kelly has been very clear that he and everyone at HQ know what they have. this is the wait and see who jumps in first. Cytodyn is not building the BP infrastructure to go at it alone.
strategy is very different now. this is not the garage band it once was, way too many top level people involved to beg for pennies. before p2 trial data, the response was likely come back when you have something to back this up, they have that now.